Felbamate: consensus of current clinical experience.
An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.
Pellock
John M
JM
Virginia Commonwealth University, Medical College of Virginia, PO Box 980211, 1001 E. Marshall St., 1st floor, Richmond, VA 23298, USA. jpellock@hsc.vcu.edu
Faught
Edward
E
Leppik
Ilo E
IE
Shinnar
Shlomo
S
Zupanc
Mary L
ML
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000401:mortality; D000078328:Felbamate; D006801:Humans; D007806:Language Disorders / Q000188:drug therapy*; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D048448:Phenylcarbamates; D011409:Propylene Glycols; D000078328:Felbamate